vimarsana.com
Home
Live Updates
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financ
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financ
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
– Product development focused on the production of powder formulations of oat beta glucan and avenanthramides for cosmeceuticals market – Technology development focused on the PGX pilot...
Related Keywords
Austria ,
Canada ,
China ,
Montreal ,
Quebec ,
Vienna ,
Wien ,
Canadian ,
Austrian ,
Gilles Gagnon ,
Beta Glucan ,
Prozesstechnologie Gmb ,
Jenene Thomas ,
Corealis Inc ,
Ceapro Inc ,
Angiogenesis Foundation ,
Nasdaq ,
Energy Booster ,
Mcmaster University ,
Montreal Heart Institute ,
Pipeline Development ,
Manufacturing Services ,
Expanded Technology ,
Technology Avenanthramides ,
Clinical Development ,
Corporate Communications Advisor ,
Clinical Trial ,
Healing Tissue Regeneration ,
Third Quarter ,
Nine Month Period Ended September ,
Interim Consolidated Balance Sheets ,
Interim Consolidated Statements ,
Cash Flows ,
Months Ended September ,
Corporate Communications ,
Markets ,